Ashton Anna, Jagannath Aarti
Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
Front Neurosci. 2020 Jun 23;14:636. doi: 10.3389/fnins.2020.00636. eCollection 2020.
Sleep and circadian rhythm disruption (SCRD) is a common feature of schizophrenia, and is associated with symptom severity and patient quality of life. It is commonly manifested as disturbances to the sleep/wake cycle, with sleep abnormalities occurring in up to 80% of patients, making it one of the most common symptoms of this disorder. Severe circadian misalignment has also been reported, including non-24 h periods and phase advances and delays. In parallel, there are alterations to physiological circadian parameters such as body temperature and rhythmic hormone production. At the molecular level, alterations in the rhythmic expression of core clock genes indicate a dysfunctional circadian clock. Furthermore, genetic association studies have demonstrated that mutations in several clock genes are associated with a higher risk of schizophrenia. Collectively, the evidence strongly suggests that sleep and circadian disruption is not only a symptom of schizophrenia but also plays an important causal role in this disorder. The alterations in dopamine signaling that occur in schizophrenia are likely to be central to this role. Dopamine is well-documented to be involved in the regulation of the sleep/wake cycle, in which it acts to promote wakefulness, such that elevated dopamine levels can disturb sleep. There is also evidence for the influence of dopamine on the circadian clock, such as through entrainment of the master clock in the suprachiasmatic nuclei (SCN), and dopamine signaling itself is under circadian control. Therefore dopamine is closely linked with sleep and the circadian system; it appears that they have a complex, bidirectional relationship in the pathogenesis of schizophrenia, such that disturbances to one exacerbate abnormalities in the other. This review will provide an overview of the evidence for a role of SCRD in schizophrenia, and examine the interplay of this with altered dopamine signaling. We will assess the evidence to suggest common underlying mechanisms in the regulation of sleep/circadian rhythms and the pathophysiology of schizophrenia. Improvements in sleep are associated with improvements in symptoms, along with quality of life measures such as cognitive ability and employability. Therefore the circadian system holds valuable potential as a new therapeutic target for this disorder.
睡眠和昼夜节律紊乱(SCRD)是精神分裂症的一个常见特征,与症状严重程度和患者生活质量相关。它通常表现为睡眠/觉醒周期的紊乱,高达80%的患者会出现睡眠异常,这使其成为该疾病最常见的症状之一。也有严重昼夜节律失调的报道,包括非24小时周期以及相位提前和延迟。与此同时,生理昼夜节律参数如体温和节律性激素分泌也会发生改变。在分子水平上,核心生物钟基因节律性表达的改变表明生物钟功能失调。此外,基因关联研究表明,多个生物钟基因的突变与精神分裂症的较高风险相关。总体而言,证据有力地表明,睡眠和昼夜节律紊乱不仅是精神分裂症的一种症状,而且在该疾病中起着重要的因果作用。精神分裂症中发生的多巴胺信号改变可能是这一作用的核心。多巴胺参与睡眠/觉醒周期的调节已有充分记录,它在其中起到促进觉醒的作用,因此多巴胺水平升高会干扰睡眠。也有证据表明多巴胺对生物钟有影响,比如通过对视交叉上核(SCN)主生物钟的同步作用实现,而且多巴胺信号本身也受昼夜节律控制。因此多巴胺与睡眠和昼夜节律系统密切相关;在精神分裂症的发病机制中,它们似乎存在复杂的双向关系,以至于一方的紊乱会加剧另一方的异常。本综述将概述SCRD在精神分裂症中作用的证据,并探讨其与多巴胺信号改变的相互作用。我们将评估证据以表明睡眠/昼夜节律调节和精神分裂症病理生理学中存在共同的潜在机制。睡眠改善与症状改善以及认知能力和就业能力等生活质量指标的改善相关。因此,昼夜节律系统作为该疾病的一个新治疗靶点具有宝贵的潜力。